source
- FDA issues warning letters to drugmakers in China, India and the US over GMP violationsThe U.S. Food and Drug Administration has issued warning letters to a number of manufacturers in China, India and the United States. The letters cite multiple violations of good manufacturing prac…
- Bausch + Lomb moves dry-eye eye drop to Phase 3 despite missing primary endpoint in Phase 2Bausch + Lomb reported results of a Phase 2 trial of its dual-action dry-eye eye drop, which combines 5% lifitegrast (the active ingredient in Xiidra) with perfluorohexyloctane (PHFO, sold as Miebo…